ClinicalTrials.gg
CompletedNCT03342898Updated Oct 8, 2020Results posted

Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) Administered With a Yellow Fever Vaccine in Adults

A Phase 3 interventional study of YF-17D and TDV in Dengue, sponsored by Takeda. Completed at 11 sites in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-10-08.

Sponsored by Takeda · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
900
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies in Dengue by Takeda — 2 open to participants now, 5 under way, 3 of them phase 3. Dengue · Takeda.

Enrollment
4th of 15
900 · median 400
Started
2018
with 2 others
Phase 3
9 of 17
1 open now
Registered
6th of 17
by date

Among the 17 studies in Dengue by Takeda, this one is the 4th largest by enrollment of the 15 interventional ones that give a count, is one of 3 that started in 2018, is one of 9 in phase 3, and was the 6th registered.

Dengue

283 studies on the registry are indexed under Dengue; 44 are open to participants now.

Browse Dengue studies →

Open to participants now

2 of the 17 studies in Dengue by Takeda are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 27 Dengue studies recruiting now, 16 (59%) set no upper age limit and 11 (41%) stop at 75 or younger; 16 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Dengue by Takeda, or all of them as a file.
02

Study summary

The main purpose of this study is to assess the immunogenicity and safety of the concomitant and sequential administration of yellow fever (YF) vaccine and tetravalent dengue vaccine (TDV) in healthy participants aged 18 to 60 years living in country non-endemic for both dengue and YF.

Read the detailed description

The vaccine tested in this study is TDV also known as TAK-003 (DENVax). TDV with concomitant and sequential administration of yellow fever (YF-17D) vaccine will be tested to assess immunogenicity and safety in healthy adult participants in non-endemic area(s) for both dengue and YF.

The study will enroll 900 healthy participants. Participants will be randomized to 3 groups in 1:1:1 ratio and will be administered concomitantly and sequentially. The 3 groups are:

  • Group 1: YF-17D vaccine + placebo concomitantly administered on Day 1, first dose of TDV administered on Day 90 and second dose of TDV administered on Day 180.
  • Group 2: first dose of TDV + placebo concomitantly administered on Day 1, second dose of TDV administered on Day 90 and YF-17D vaccine administered on Day 180.
  • Group 3: first dose of TDV + YF-17D vaccine concomitantly administered on Day 1, second dose of TDV administered on Day 90 and placebo administered on Day 180.

This multi-center trial will be conducted in the United States. The overall time to participate in this study is 360 days. Participants will make multiple visits to the clinic with a 6-month follow up including a final visit at Day 360 for a follow-up assessment.

03

Conditions studied

  • Dengue

Browse trials for

Keywords

  • Drug Therapy
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Is aged 18 to 60 years inclusive, at the time of randomization.
  2. Is in good health at the time of entry into the trial as determined by medical history, physical examination (including vital signs), and the clinical judgment of the Investigator.

Exclusion criteria

Exclusion Criteria:

  1. Has an elevated oral temperature ≥ 38°C (100.4°F) within 3 days of the intended date of vaccination.
  2. Has , warnings and/or precautions to vaccination with the YF-17D vaccine as specified within the product information (especially history of thymus dysfunction).
  3. Female participant who are pregnant or breastfeeding
  4. Has any history of progressive or severe neurologic disorder, seizure disorder or neuro-inflammatory disease (e.g., Guillain-Barre syndrome) or suspected impairment/alteration of immune function.
  5. Has (BMI) greater than or equal to 35 kg/m\^2 (=weight in kg/[height in meters\^2]).
  6. Is intent to travel to dengue or YF endemic countries during the trial period.
  7. Has received any other vaccines within 14 days (for inactivated vaccines) or 28 days (for ) prior to enrollment in this trial or who are planning to receive any non-trial vaccine within 28 days of trial vaccine administration.
  8. Has previous and planned vaccination (during the trial conduct), against any flavivirus including dengue, YF, Japanese encephalitis (JE) or tick-borne encephalitis viruses.
  9. Has previous participation in any clinical trial of a dengue or other flavivirus (e.g., West Nile [WN] virus) candidate vaccine, except for participants who received placebo in those trials.
  10. Has a current or previous infection with a flavivirus such as dengue, Zika, YF, JE, WN fever, or Saint Louis encephalitis viruses and participants with a history of prolonged (≥1 year) habitation in a dengue endemic area.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
900 participants (actual)

Study arms

  • Experimental
    Group 1: YF-17D + Placebo/TDV/TDV

    YF-17D vaccine, 0.5 mL injection, subcutaneously (SC) plus YF 17D + TDV placebo-matching 0.5 mL, injection, SC on Day 1, followed by TDV, 0.5 mL, injection, SC on Day 90 (first dose), followed by TDV, 0.5 mL, injection, SC on Day 180 (second dose).

    Biological: YF-17D · Biological: TDV · Drug: Placebo

  • Experimental
    Group 2: TDV + Placebo/TDV/YF-17D

    TDV, 0.5 mL, injection, SC plus TDV placebo-matching, 0.5 mL injection, SC on Day 1 (first dose), followed by TDV, 0.5 mL, injection, SC on Day 90 (second dose), followed by YF-17D vaccine, 0.5 mL, injection, SC on Day 180.

    Biological: YF-17D · Biological: TDV · Drug: Placebo

  • Experimental
    Group 3: TDV + YF-17D/TDV/Placebo

    TDV, 0.5 mL, injection, SC plus YF-17D vaccine, 0.5 mL, injection, SC on Day 1 (first dose), followed by TDV, 0.5 mL, injection, SC on day 90 (second dose), followed by TDV + YF 17D placebo-matching, 0.5 mL, injection, SC on Day 180.

    Biological: YF-17D · Biological: TDV · Drug: Placebo

Interventions

  • BiologicalYF-17D

    YF-17D SC injection.

  • BiologicalTDV

    TDV SC injection.

    Also known as: TAK-003, DENVax

  • DrugPlacebo

    Normal Saline (0.9% NaCl) SC injection.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Are YF and Dengue Virus (DENV)-Naive at Baseline and Are Seroprotected Against YF on Day 30 as Measured by Plaque Reduction Neutralization Test (PRNT)

    Seroprotection was defined as reciprocal anti-YF neutralizing antibody titer ≥10. Immunological naivety to YF and DENV was defined as Baseline reciprocal neutralizing antibody titers \<10 for YF and for the 4 dengue serotypes. The 95% CI was calculated using exact Clopper-Pearson method.

    Time frame: Day 30

Secondary outcomes

  1. Geometric Mean Titers (GMTs) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes on Days 30, 90, 120, 180 and 210 in Participants YF and DENV-naive at Baseline

    GMTs of neutralizing antibodies was measured by microneutralization test 50% \[MNT50\] for each of the 4 dengue serotypes. The 4 DENV serotypes are DENV-1, DENV-2, DENV-3 and DENV-4.

    Time frame: Pre-second and -third vaccination (Days 90 and 180, respectively); and 1 month post -first, second, and third vaccination (Days 30, 120, and 210, respectively)

  2. Percentage of Participants Who Are Seropositive for Each of the 4 Dengue Serotypes on Days 30, 90, 120, 180 and 210 in Participants YF and DENV-naive at Baseline

    Seropositivity rate was defined as the percentage of seropositive participants as derived from the titers of dengue-neutralizing antibodies. Seropositivity was defined as a reciprocal neutralizing titer ≥10. Seropositivity for each dengue serotype were analyzed and was summarized as: DENV-1, DENV-2, DENV-3, and DENV-4.

    Time frame: Pre-second and -third vaccination (Days 90 and 180, respectively); and 1-month post -first, -second, and -third vaccination (Days 30, 120, and 210, respectively)

  3. Percentage of Participants Who Are Seropositive for Multiple (2, 3 or 4) Dengue Serotypes on Days 30, 90, 120, 180 and 210 in Participants YF and DENV-naive at Baseline

    Seropositivity rate was defined as the percentage of seropositive participants, as derived from the titers of dengue-neutralizing antibodies. Seropositivity was defined as a reciprocal neutralizing titer ≥10. Seropositivity for multiple dengue serotypes were summarized in the following categories: at least bivalent, at least trivalent and tetravalent.

    Time frame: Pre-second and -third vaccination (Days 90 and 180, respectively); and 1-month post -first, second, and -third vaccination (Days 30, 120, and 210, respectively)

  4. Percentage of YF and DENV-naive Participants at Baseline Who Are Seroprotected Against YF on Day 210 as Measured by PRNT

    Seroprotection was defined as reciprocal anti-YF neutralizing antibody titer ≥10.

    Time frame: 1-month post third vaccination (Day 210)

  5. Geometric Mean Titers (GMTs) of Anti-YF Neutralizing Antibodies at Day 30 in Participants YF and DENV-Naive at Baseline

    Geometric mean titers of YF neutralizing antibodies was measured by plaque reduction neutralization test.

    Time frame: 1-month post-first vaccination (Day 30)

  6. Geometric Mean Titers (GMTs) of Anti-YF Neutralizing Antibodies at Day 210 in Participants YF and DENV-Naive at Baseline

    Geometric mean titers of YF neutralizing antibodies was measured by plaque reduction neutralization test.

    Time frame: 1-month post-third vaccination (Day 210)

  7. Percentage of Participants With Solicited Local (Injection Site) Adverse Events (AEs) Following Each Vaccination Dose by Severity

    An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a trial vaccine; it does not necessarily have to have a causal relationship with trial vaccine administration. Solicited local injection site AEs recorded from participant's-diary. Severity grade at injection site for pain: Grade 0 (No Pain), 1 (did not interfere with daily activity), 2 (interference with daily activity with or without treatment) and 3 (prevents daily activity with or without treatment). For erythema: grade 0 (\<25 mm), 1 (\>25-≤50 mm), 2 (\>50-≤100 mm) and 3 (\>100 mm). For swelling: grade 0 (\<25 mm), 1 (\>25-≤50 mm), 2 (\>50-≤100 mm) and 3 (\>100 mm). Percentages were rounded off for each category. For the first vaccination (Vac.) YF is given in Arm 1 (A1) and TDV is given in Arm 2 (A2). A1 = YF for Group 1, Placebo for Group 2, and YF for Group 3; A2 = Placebo for Group 1, TDV for Group 2, and TDV for Group 3.

    Time frame: Within 7 Days of each Vaccination (day of vaccination + 6 days)

  8. Percentage of Participants With Solicited Systemic Adverse Events Following Each Vaccination Dose by Severity

    Solicited systemic AEs (fever, headache, asthenia, malaise, and myalgia) recorded from participant's-diary. Severity grades for headache are grade 0 (none), 1 (mild: no interference with daily activity), 2 (moderate: interference with daily activity with or without treatment) and 3 (severe: prevents normal activity with or without treatment). Severity grades for asthenia, malaise and myalgia is grade 0 (none), 1 (mild: no interference with daily activity), 2 (moderate: interference with daily activity), 3 (severe: prevents daily activity). Fever is defined as greater than or equal to 38º C or 100.4º C. Fever was excluded from the overall count as no severity grading was applied for it. Percentages were rounded off for each category.

    Time frame: Within 14 Days of each Vaccination (day of vaccination + 13 days)

  9. Percentage of Participants With Any Unsolicited Adverse Events (AEs)

    An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a trial vaccine; it does not necessarily have to have a causal relationship with trial vaccine administration.

    Time frame: Within 28 days (day of vaccination + 27 days) after each vaccination

  10. Percentage of Participants With Medically Attended Adverse Events (MAAEs)

    MAAEs are defined as AEs leading to an unscheduled visit to or by a healthcare professional including visits to an emergency department, but not fulfilling seriousness criteria.

    Time frame: From first vaccination (Day 1) through end of study (Day 360)

  11. Percentage of Participants With Serious Adverse Events (SAEs)

    An SAE is defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, leads to a congenital anomaly/birth defect in the offspring of a participant, is an important medical event that may require intervention to prevent any of the above mentioned criteria and/or may expose the subject to danger, even though the event is not immediately life threatening or fatal or does not result in hospitalization.

    Time frame: From first vaccination (Day 1) through end of study (Day 360)

07

Results

Posted Oct 8, 2020

Participant flow

Participants took part in the study at 11 investigative sites in the United States from 28 Feb 2018 to 22 May 2019.

Participant flow — Overall Study
MilestoneGroup 1: YF-17D + Placebo/TDV/TDVGroup 2: TDV + Placebo/TDV/YF-17DGroup 3: TDV + YF-17D/TDV/Placebo
Started300300300
Completed246247246
Not completed545354
Withdrew: Adverse event310
Withdrew: Lost to follow-up444042
Withdrew: Withdrawal of consent5911
Withdrew: Death011
Withdrew: Reason not specified220

Outcome measures

PrimaryPercentage of Participants Who Are YF and Dengue Virus (DENV)-Naive at Baseline and Are Seroprotected Against YF on Day 30 as Measured by Plaque Reduction Neutralization Test (PRNT)

Seroprotection was defined as reciprocal anti-YF neutralizing antibody titer ≥10. Immunological naivety to YF and DENV was defined as Baseline reciprocal neutralizing antibody titers \<10 for YF and for the 4 dengue serotypes. The 95% CI was calculated using exact Clopper-Pearson method.

Time frame:
Day 30
Reported as:
Number · percentage of participants
Percentage of Participants Who Are YF and Dengue Virus (DENV)-Naive at Baseline and Are Seroprotected Against YF on Day 30 as Measured by Plaque Reduction Neutralization Test (PRNT)
percentage of participantsGroup 1: YF-17D + Placebo/TDV/TDVGroup 2: TDV + Placebo/TDV/YF-17DGroup 3: TDV + YF-17D/TDV/Placebo
Percentage of Participants Who Are YF and Dengue Virus (DENV)-Naive at Baseline and Are Seroprotected Against YF on Day 30 as Measured by Plaque Reduction Neutralization Test (PRNT)99.5 (97.4 to 100.0)9.8 (6.3 to 14.4)99.1 (96.9 to 99.9)
Statistical analysis
  • Group 1: YF-17D + Placebo/TDV/TDV vs Group 3: TDV + YF-17D/TDV/Placebo · Seroprotection rate difference: 0.40 · 95% CI -1.85 to 2.69The Newcombe score method was used to compute the 95% CI of the seroprotection rate difference.
SecondaryGeometric Mean Titers (GMTs) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes on Days 30, 90, 120, 180 and 210 in Participants YF and DENV-naive at Baseline

GMTs of neutralizing antibodies was measured by microneutralization test 50% \[MNT50\] for each of the 4 dengue serotypes. The 4 DENV serotypes are DENV-1, DENV-2, DENV-3 and DENV-4.

Time frame:
Pre-second and -third vaccination (Days 90 and 180, respectively); and 1 month post -first, second, and third vaccination (Days 30, 120, and 210, respectively)
Reported as:
Geometric mean · titer
Geometric Mean Titers (GMTs) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes on Days 30, 90, 120, 180 and 210 in Participants YF and DENV-naive at Baseline
titerGroup 1: YF-17D + Placebo/TDV/TDVGroup 2: TDV + Placebo/TDV/YF-17DGroup 3: TDV + YF-17D/TDV/Placebo
Day 30, DENV-16.0 (5.4 to 6.7)226.2 (178.7 to 286.4)119.4 (93.0 to 153.4)
Day 30, DENV-27.7 (6.6 to 9.0)5431.1 (3930.2 to 7505.3)650.8 (438.1 to 966.7)
Day 30, DENV-35.8 (5.2 to 6.4)172.0 (129.4 to 228.5)70.9 (54.1 to 92.9)
Day 30, DENV-46.1 (5.4 to 6.9)142.0 (108.7 to 185.4)49.8 (39.3 to 63.1)
Day 90, DENV-16.0 (5.5 to 6.6)147.5 (114.6 to 189.7)95.1 (74.0 to 122.2)
Day 90, DENV-27.8 (6.6 to 9.2)2846.5 (2273.6 to 3563.7)1547.2 (1198.1 to 1998.0)
Day 90, DENV-35.9 (5.3 to 6.5)73.1 (58.3 to 91.7)70.1 (57.3 to 85.7)
Day 90, DENV-45.9 (5.3 to 6.4)56.1 (45.0 to 70.0)49.1 (41.0 to 58.8)
Day 120, DENV-1403.9 (335.3 to 486.6)297.1 (239.8 to 368.1)182.6 (145.5 to 229.2)
Day 120, DENV-24691.3 (3688.6 to 5966.4)2616.1 (2133.1 to 3208.4)1947.7 (1639.9 to 2313.2)
Day 120, DENV-3636.4 (525.6 to 770.5)131.4 (110.5 to 156.3)104.5 (87.9 to 124.1)
Day 120, DENV-4678.5 (568.7 to 809.4)111.8 (94.5 to 132.1)97.7 (81.4 to 117.3)
Day 180, DENV-1251.4 (209.0 to 302.3)227.0 (177.4 to 290.4)147.0 (115.8 to 186.6)
Day 180, DENV-22413.5 (2038.6 to 2857.3)1959.3 (1584.1 to 2423.5)1800.0 (1535.8 to 2109.7)
Day 180, DENV-3342.3 (294.6 to 397.9)84.9 (70.1 to 102.8)75.8 (65.2 to 88.3)
Day 180, DENV-4358.4 (302.8 to 424.2)83.7 (69.9 to 100.3)69.6 (59.0 to 82.3)
Day 210, DENV-1267.5 (221.5 to 323.2)679.9 (549.7 to 841.0)138.2 (108.3 to 176.2)
Day 210, DENV-22248.0 (1902.3 to 2656.6)3798.1 (3139.4 to 4595.0)1688.0 (1431.7 to 1990.1)
Day 210, DENV-3301.8 (262.7 to 346.6)406.4 (345.4 to 478.1)64.3 (54.3 to 76.2)
Day 210, DENV-4347.4 (297.5 to 405.6)436.5 (374.7 to 508.5)56.6 (46.9 to 68.2)
Statistical analysis
  • Group 2: TDV + Placebo/TDV/YF-17D vs Group 3: TDV + YF-17D/TDV/Placebo · Geometric mean ratio: 1.6 · 95% CI 1.19 to 2.22Analysis of variance (ANOVA) model was used for analysis, including log-transformed value of titer as the dependent variable and trial group as a factor.
  • Group 2: TDV + Placebo/TDV/YF-17D vs Group 3: TDV + YF-17D/TDV/Placebo · Geometric mean ratio: 1.3 · 95% CI 1.03 to 1.75ANOVA model was used for analysis, including log-transformed value of titer as the dependent variable and trial group as a factor.
  • Group 2: TDV + Placebo/TDV/YF-17D vs Group 3: TDV + YF-17D/TDV/Placebo · Geometric mean ratio: 1.3 · 95% CI 0.99 to 1.61ANOVA model was used for analysis, including log-transformed value of titer as the dependent variable and trial group as a factor.
  • Group 2: TDV + Placebo/TDV/YF-17D vs Group 3: TDV + YF-17D/TDV/Placebo · Geometric mean ratio: 1.1 · 95% CI 0.89 to 1.46ANOVA model was used for analysis, including log-transformed value of titer as the dependent variable and trial group as a factor.
SecondaryPercentage of Participants Who Are Seropositive for Each of the 4 Dengue Serotypes on Days 30, 90, 120, 180 and 210 in Participants YF and DENV-naive at Baseline

Seropositivity rate was defined as the percentage of seropositive participants as derived from the titers of dengue-neutralizing antibodies. Seropositivity was defined as a reciprocal neutralizing titer ≥10. Seropositivity for each dengue serotype were analyzed and was summarized as: DENV-1, DENV-2, DENV-3, and DENV-4.

Time frame:
Pre-second and -third vaccination (Days 90 and 180, respectively); and 1-month post -first, -second, and -third vaccination (Days 30, 120, and 210, respectively)
Reported as:
Number · percentage of participants
Percentage of Participants Who Are Seropositive for Each of the 4 Dengue Serotypes on Days 30, 90, 120, 180 and 210 in Participants YF and DENV-naive at Baseline
percentage of participantsGroup 1: YF-17D + Placebo/TDV/TDVGroup 2: TDV + Placebo/TDV/YF-17DGroup 3: TDV + YF-17D/TDV/Placebo
Day 30, DENV-16.5 (3.4 to 11.1)93.3 (88.8 to 96.4)87.6 (81.9 to 92.0)
Day 30, DENV-215.8 (10.8 to 21.8)95.9 (92.0 to 98.2)88.1 (82.6 to 92.4)
Day 30, DENV-34.3 (1.9 to 8.4)88.1 (82.7 to 92.3)80.5 (74.1 to 86.0)
Day 30, DENV-47.1 (3.8 to 11.8)89.6 (84.4 to 93.6)78.4 (71.7 to 84.1)
Day 90, DENV-18.3 (4.8 to 13.2)90.4 (85.5 to 94.0)89.4 (84.1 to 93.4)
Day 90, DENV-214.6 (9.9 to 20.4)97.1 (93.8 to 98.9)94.2 (89.8 to 97.1)
Day 90, DENV-35.7 (2.9 to 10.0)84.6 (79.0 to 89.2)90.5 (85.4 to 94.3)
Day 90, DENV-46.3 (3.3 to 10.7)84.6 (79.0 to 89.2)89.4 (84.1 to 93.4)
Day 120, DENV-199.4 (96.9 to 100.0)99.5 (97.2 to 100.0)99.4 (96.9 to 100.0)
Day 120, DENV-299.4 (96.9 to 100.0)98.5 (95.6 to 99.7)99.4 (96.9 to 100.0)
Day 120, DENV-398.9 (95.9 to 99.9)98.5 (95.6 to 99.7)98.3 (95.1 to 99.6)
Day 120, DENV-499.4 (96.9 to 100.0)99.0 (96.4 to 99.9)97.7 (94.3 to 99.4)
Day 180, DENV-199.0 (96.3 to 99.9)97.1 (93.8 to 98.9)95.8 (91.8 to 98.2)
Day 180, DENV-2100.0 (98.1 to 100.0)97.6 (94.5 to 99.2)99.5 (97.1 to 100.0)
Day 180, DENV-399.5 (97.1 to 100.0)92.8 (88.4 to 95.9)96.3 (92.5 to 98.5)
Day 180, DENV-499.0 (96.3 to 99.9)96.6 (93.2 to 98.6)96.8 (93.2 to 98.8)
Day 210, DENV-1100.0 (97.9 to 100.0)99.5 (97.1 to 100.0)96.6 (92.7 to 98.7)
Day 210, DENV-2100.0 (97.9 to 100.0)99.5 (97.1 to 100.0)99.4 (96.9 to 100.0)
Day 210, DENV-3100.0 (97.9 to 100.0)99.5 (97.1 to 100.0)93.2 (88.4 to 96.4)
Day 210, DENV-499.4 (96.8 to 100.0)99.5 (97.1 to 100.0)94.3 (89.8 to 97.2)
SecondaryPercentage of Participants Who Are Seropositive for Multiple (2, 3 or 4) Dengue Serotypes on Days 30, 90, 120, 180 and 210 in Participants YF and DENV-naive at Baseline

Seropositivity rate was defined as the percentage of seropositive participants, as derived from the titers of dengue-neutralizing antibodies. Seropositivity was defined as a reciprocal neutralizing titer ≥10. Seropositivity for multiple dengue serotypes were summarized in the following categories: at least bivalent, at least trivalent and tetravalent.

Time frame:
Pre-second and -third vaccination (Days 90 and 180, respectively); and 1-month post -first, second, and -third vaccination (Days 30, 120, and 210, respectively)
Reported as:
Number · percentage of participants
Percentage of Participants Who Are Seropositive for Multiple (2, 3 or 4) Dengue Serotypes on Days 30, 90, 120, 180 and 210 in Participants YF and DENV-naive at Baseline
percentage of participantsGroup 1: YF-17D + Placebo/TDV/TDVGroup 2: TDV + Placebo/TDV/YF-17DGroup 3: TDV + YF-17D/TDV/Placebo
Day 30, At Least Bivalent5.4 (2.6 to 9.8)96.9 (93.4 to 98.9)90.8 (85.7 to 94.6)
Day 30, At Least Trivalent4.9 (2.3 to 9.1)91.7 (86.9 to 95.2)81.6 (75.3 to 86.9)
Day 30, Tetravalent3.8 (1.5 to 7.7)79.3 (72.9 to 84.8)65.9 (58.6 to 72.7)
Day 90, At Least Bivalent6.3 (3.3 to 10.7)95.7 (91.9 to 98.0)94.7 (90.5 to 97.4)
Day 90, At Least Trivalent5.7 (2.9 to 10.0)87.0 (81.7 to 91.3)88.9 (83.5 to 93.0)
Day 90, Tetravalent5.7 (2.9 to 10.0)75.5 (69.1 to 81.2)82.0 (75.8 to 87.2)
Day 120, At Least Bivalent99.4 (96.9 to 100.0)99.5 (97.2 to 100.0)99.4 (96.9 to 100.0)
Day 120, At Least Trivalent99.4 (96.9 to 100.0)99.5 (97.2 to 100.0)98.3 (95.1 to 99.6)
Day 120, Tetravalent98.9 (95.9 to 99.9)97.0 (93.5 to 98.9)97.7 (94.3 to 99.4)
Day 180, At Least Bivalent99.5 (97.1 to 100.0)99.0 (96.6 to 99.9)98.9 (96.2 to 99.9)
Day 180, At Least Trivalent99.0 (96.3 to 99.9)97.6 (94.5 to 99.2)98.4 (95.4 to 99.7)
Day 180, Tetravalent99.0 (96.3 to 99.9)88.0 (82.8 to 92.1)91.5 (86.6 to 95.1)
Day 210, At Least Bivalent100.0 (97.9 to 100.0)99.5 (97.1 to 100.0)98.9 (96.0 to 99.9)
Day 210, At Least Trivalent100.0 (97.9 to 100.0)99.5 (97.1 to 100.0)96.0 (92.0 to 98.4)
Day 210, Tetravalent99.4 (96.8 to 100.0)99.5 (97.1 to 100.0)89.2 (83.7 to 93.4)
SecondaryPercentage of YF and DENV-naive Participants at Baseline Who Are Seroprotected Against YF on Day 210 as Measured by PRNT

Seroprotection was defined as reciprocal anti-YF neutralizing antibody titer ≥10.

Time frame:
1-month post third vaccination (Day 210)
Reported as:
Number · percentage of participants
Percentage of YF and DENV-naive Participants at Baseline Who Are Seroprotected Against YF on Day 210 as Measured by PRNT
percentage of participantsGroup 1: YF-17D + Placebo/TDV/TDVGroup 2: TDV + Placebo/TDV/YF-17DGroup 3: TDV + YF-17D/TDV/Placebo
Percentage of YF and DENV-naive Participants at Baseline Who Are Seroprotected Against YF on Day 210 as Measured by PRNT100.0 (97.9 to 100.0)98.4 (95.4 to 99.7)98.9 (96.0 to 99.9)
SecondaryGeometric Mean Titers (GMTs) of Anti-YF Neutralizing Antibodies at Day 30 in Participants YF and DENV-Naive at Baseline

Geometric mean titers of YF neutralizing antibodies was measured by plaque reduction neutralization test.

Time frame:
1-month post-first vaccination (Day 30)
Reported as:
Geometric mean · titer
Geometric Mean Titers (GMTs) of Anti-YF Neutralizing Antibodies at Day 30 in Participants YF and DENV-Naive at Baseline
titerGroup 1: YF-17D + Placebo/TDV/TDVGroup 2: TDV + Placebo/TDV/YF-17DGroup 3: TDV + YF-17D/TDV/Placebo
Geometric Mean Titers (GMTs) of Anti-YF Neutralizing Antibodies at Day 30 in Participants YF and DENV-Naive at Baseline4245.7 (3526.5 to 5111.6)6.0 (5.5 to 6.6)4321.7 (3652.5 to 5113.6)
Statistical analysis
  • Group 1: YF-17D + Placebo/TDV/TDV vs Group 3: TDV + YF-17D/TDV/Placebo · Geometric mean ratio: 1.0 · 95% CI 0.77 to 1.26ANOVA model was used for analyses, including the log-transformed value of titer as the dependent variable and trial group as a factor.
SecondaryGeometric Mean Titers (GMTs) of Anti-YF Neutralizing Antibodies at Day 210 in Participants YF and DENV-Naive at Baseline

Geometric mean titers of YF neutralizing antibodies was measured by plaque reduction neutralization test.

Time frame:
1-month post-third vaccination (Day 210)
Reported as:
Geometric mean · titer
Geometric Mean Titers (GMTs) of Anti-YF Neutralizing Antibodies at Day 210 in Participants YF and DENV-Naive at Baseline
titerGroup 1: YF-17D + Placebo/TDV/TDVGroup 2: TDV + Placebo/TDV/YF-17DGroup 3: TDV + YF-17D/TDV/Placebo
Geometric Mean Titers (GMTs) of Anti-YF Neutralizing Antibodies at Day 210 in Participants YF and DENV-Naive at Baseline2341.6 (1938.2 to 2829.0)3078.2 (2452.0 to 3864.4)1089.1 (888.1 to 1335.7)
SecondaryPercentage of Participants With Solicited Local (Injection Site) Adverse Events (AEs) Following Each Vaccination Dose by Severity

An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a trial vaccine; it does not necessarily have to have a causal relationship with trial vaccine administration. Solicited local injection site AEs recorded from participant's-diary. Severity grade at injection site for pain: Grade 0 (No Pain), 1 (did not interfere with daily activity), 2 (interference with daily activity with or without treatment) and 3 (prevents daily activity with or without treatment). For erythema: grade 0 (\<25 mm), 1 (\>25-≤50 mm), 2 (\>50-≤100 mm) and 3 (\>100 mm). For swelling: grade 0 (\<25 mm), 1 (\>25-≤50 mm), 2 (\>50-≤100 mm) and 3 (\>100 mm). Percentages were rounded off for each category. For the first vaccination (Vac.) YF is given in Arm 1 (A1) and TDV is given in Arm 2 (A2). A1 = YF for Group 1, Placebo for Group 2, and YF for Group 3; A2 = Placebo for Group 1, TDV for Group 2, and TDV for Group 3.

Time frame:
Within 7 Days of each Vaccination (day of vaccination + 6 days)
Reported as:
Number · percentage of participants
Percentage of Participants With Solicited Local (Injection Site) Adverse Events (AEs) Following Each Vaccination Dose by Severity
percentage of participantsGroup 1: YF-17D + Placebo/TDV/TDVGroup 2: TDV + Placebo/TDV/YF-17DGroup 3: TDV + YF-17D/TDV/Placebo
After Vac. 1, Any Local AEs, A113.116.827.3
After Vac. 1, Any Local AEs, A213.144.248.9
After Vac. 1, Pain: Any Severity, A112.116.524.1
After Vac. 1, Pain: Any Severity, A212.840.042.2
After Vac. 1, Pain: Mild, A19.013.721.3
After Vac. 1, Pain: Mild, A210.035.134.0
After Vac. 1, Pain: Moderate, A13.12.52.1
After Vac. 1, Pain: Moderate, A22.44.66.7
After Vac. 1, Pain: Severe, A100.40.7
After Vac. 1, Pain: Severe, A20.30.41.4
After Vac. 1, Erythema: Any Severity, A12.41.83.9
After Vac. 1, Erythema: Any Severity, A20.719.619.5
After Vac. 1,Erythema:Mild:2.5-5(cm), A11.71.83.9
After Vac. 1,Erythema:Mild:2.5-5(cm), A2017.518.8
After Vac. 1,Erythema:Moderate:>5-<=10(cm), A10.300
After Vac. 1,Erythema:Moderate:>5-<=10(cm), A20.71.80.4
After Vac. 1,Erythema:Severe:>10(cm), A10.300
After Vac. 1,Erythema:Severe:>10(cm), A2000.4
After Vac. 1, Erythema: Missing Severity, A200.40
After Vac. 1, Swelling: Any Severity, A10.71.12.1
After Vac. 1, Swelling: Any Severity, A20.34.25.3
After Vac. 1,Swelling:Mild:2.5-5(cm), A10.31.11.8
After Vac. 1,Swelling:Mild:2.5-5(cm), A204.24.6
After Vac. 1,Swelling:Moderate:>5-<=10(cm), A1000.4
After Vac. 1,Swelling:Moderate:>5-<=10(cm), A20.300.4
After Vac. 1,Swelling:Severe:>10(cm), A10.300
After Vac. 1,Swelling:Severe:>10(cm), A2000.4
After Vac. 2, Any Local AEs31.135.935.7
After Vac. 2, Pain: Any Severity27.830.131.7
After Vac. 2, Pain: Mild23.625.827.8
After Vac. 2, Pain: Moderate3.43.52.8
After Vac. 2, Pain: Severe0.80.81.2
After Vac. 2, Erythema: Any Severity12.314.513.1
After Vac. 2,Erythema:Mild:2.5-5(cm)10.710.510.7
After Vac. 2,Erythema:Moderate:>5-<=10(cm)1.13.12.4
After Vac. 2,Erythema:Severe:>10(cm)0.400
After Vac. 2, Erythema: Missing Severity00.80
After Vac. 2, Swelling: Any Severity2.75.95.6
After Vac. 2,Swelling:Mild:2.5-5(cm)2.34.34.8
After Vac. 2,Swelling:Moderate:>5-<=10(cm)0.41.60.8
After Vac. 3, Any Local AEs27.810.410.6
After Vac. 3, Pain: Any Severity24.910.49.7
After Vac. 3, Pain: Mild20.39.17.9
After Vac. 3, Pain: Moderate4.20.90.9
After Vac. 3, Pain: Severe0.40.40.9
After Vac. 3, Erythema: Any Severity9.70.40.9
After Vac. 3,Erythema:Mild:2.5-5(cm)8.500.4
After Vac. 3,Erythema:Moderate:>5-<=10(cm)0.40.40
After Vac. 3,Erythema:Severe:>10(cm)000.4
After Vac. 3, Erythema: Missing Severity0.800
After Vac. 3, Swelling: Any Severity4.200
After Vac. 3,Swelling:Mild:2.5-5(cm)3.400
After Vac. 3, Swelling: Missing Severity0.800
SecondaryPercentage of Participants With Solicited Systemic Adverse Events Following Each Vaccination Dose by Severity

Solicited systemic AEs (fever, headache, asthenia, malaise, and myalgia) recorded from participant's-diary. Severity grades for headache are grade 0 (none), 1 (mild: no interference with daily activity), 2 (moderate: interference with daily activity with or without treatment) and 3 (severe: prevents normal activity with or without treatment). Severity grades for asthenia, malaise and myalgia is grade 0 (none), 1 (mild: no interference with daily activity), 2 (moderate: interference with daily activity), 3 (severe: prevents daily activity). Fever is defined as greater than or equal to 38º C or 100.4º C. Fever was excluded from the overall count as no severity grading was applied for it. Percentages were rounded off for each category.

Time frame:
Within 14 Days of each Vaccination (day of vaccination + 13 days)
Reported as:
Number · percentage of participants
Percentage of Participants With Solicited Systemic Adverse Events Following Each Vaccination Dose by Severity
percentage of participantsGroup 1: YF-17D + Placebo/TDV/TDVGroup 2: TDV + Placebo/TDV/YF-17DGroup 3: TDV + YF-17D/TDV/Placebo
After Vaccination 1, Any Systemic AEs43.649.851.8
After Vaccination 1, Headache: Any Severity31.833.039.9
After Vaccination 1, Headache: Mild21.522.526.0
After Vaccination 1, Headache: Moderate8.78.49.3
After Vaccination 1, Headache: Severe1.72.14.6
After Vaccination 1, Asthenia: Any Severity17.621.120.3
After Vaccination 1, Asthenia: Mild10.011.213.9
After Vaccination 1, Asthenia: Moderate5.57.74.6
After Vaccination 1, Asthenia: Severe2.12.11.8
After Vaccination 1, Malaise: Any Severity20.820.724.5
After Vaccination 1, Malaise: Mild12.811.613.8
After Vaccination 1, Malaise: Moderate6.24.68.5
After Vaccination 1, Malaise: Severe1.74.62.1
After Vaccination 1, Myalgia: Any Severity23.229.529.4
After Vaccination 1, Myalgia: Mild15.619.619.1
After Vaccination 1, Myalgia: Moderate5.57.08.5
After Vaccination 1, Myalgia: Severe2.12.81.8
After Vaccination 1, Fever: Any Severity1.46.01.1
After Vaccination 1,Fever:38.0-<38.50.33.60.4
After Vaccination 1,Fever:38.5-<39.00.31.80.7
After Vaccination 1,Fever:39.0-<39.50.30.40
After Vaccination 1,Fever:39.5-<40.000.40
After Vaccination 1,Fever:≥41.00.300
After Vaccination 2, Any Systemic AEs33.329.331.7
After Vaccination 2, Headache: Any Severity22.715.621.0
After Vaccination 2, Headache: Mild13.310.211.9
After Vaccination 2, Headache: Moderate6.44.37.1
After Vaccination 2, Headache: Severe3.01.22.0
After Vaccination 2, Asthenia: Any Severity13.38.611.5
After Vaccination 2, Asthenia: Mild8.32.76.7
After Vaccination 2, Asthenia: Moderate3.84.32.4
After Vaccination 2, Asthenia: Severe1.11.62.4
After Vaccination 2, Malaise: Any Severity14.09.89.9
After Vaccination 2, Malaise: Mild7.64.34.4
After Vaccination 2, Malaise: Moderate4.54.34.0
After Vaccination 2, Malaise: Severe1.91.21.6
After Vaccination 2, Myalgia: Any Severity20.818.820.2
After Vaccination 2, Myalgia: Mild14.413.312.3
After Vaccination 2, Myalgia: Moderate5.34.35.2
After Vaccination 2, Myalgia: Severe1.11.22.8
After Vaccination 2, Fever: Any Severity3.11.21.2
After Vaccination 2,Fever:38.0-<38.51.50.40.4
After Vaccination 2,Fever:38.5-<39.01.20.80.4
After Vaccination 2,Fever:39.0-<39.50.400
After Vaccination 2,Fever:39.5-<40.0000.4
After Vaccination 3, Any Systemic AEs24.427.422.8
After Vaccination 3, Headache: Any Severity17.217.420.2
After Vaccination 3, Headache: Mild10.111.313.6
After Vaccination 3, Headache: Moderate6.34.84.8
After Vaccination 3, Headache: Severe0.81.31.8
After Vaccination 3, Asthenia: Any Severity10.59.17.0
After Vaccination 3, Asthenia: Mild6.37.43.9
After Vaccination 3, Asthenia: Moderate3.81.72.6
After Vaccination 3, Asthenia: Severe0.400.4
After Vaccination 3, Malaise: Any Severity11.313.511.4
After Vaccination 3, Malaise: Mild6.39.17.9
After Vaccination 3, Malaise: Moderate3.83.52.6
After Vaccination 3, Malaise: Severe1.30.90.9
After Vaccination 3, Myalgia: Any Severity12.612.27.9
After Vaccination 3, Myalgia: Mild7.67.84.8
After Vaccination 3, Myalgia: Moderate3.83.92.6
After Vaccination 3, Myalgia: Severe1.30.40.4
After Vaccination 3, Fever: Any Severity1.301.3
After Vaccination 3,Fever:38.0-<38.50.900.9
After Vaccination 3,Fever:38.5-<39.00.400
After Vaccination 3,Fever:39.0-<39.5000.4
SecondaryPercentage of Participants With Any Unsolicited Adverse Events (AEs)

An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a trial vaccine; it does not necessarily have to have a causal relationship with trial vaccine administration.

Time frame:
Within 28 days (day of vaccination + 27 days) after each vaccination
Reported as:
Number · percentage of participants
Percentage of Participants With Any Unsolicited Adverse Events (AEs)
percentage of participantsGroup 1: YF-17D + Placebo/TDV/TDVGroup 2: TDV + Placebo/TDV/YF-17DGroup 3: TDV + YF-17D/TDV/Placebo
After First Vaccination11.717.314.0
After Second Vaccination8.810.49.1
After Third Vaccination4.45.44.7
SecondaryPercentage of Participants With Medically Attended Adverse Events (MAAEs)

MAAEs are defined as AEs leading to an unscheduled visit to or by a healthcare professional including visits to an emergency department, but not fulfilling seriousness criteria.

Time frame:
From first vaccination (Day 1) through end of study (Day 360)
Reported as:
Number · percentage of participants
Percentage of Participants With Medically Attended Adverse Events (MAAEs)
percentage of participantsGroup 1: YF-17D + Placebo/TDV/TDVGroup 2: TDV + Placebo/TDV/YF-17DGroup 3: TDV + YF-17D/TDV/Placebo
Percentage of Participants With Medically Attended Adverse Events (MAAEs)14.315.315.3
SecondaryPercentage of Participants With Serious Adverse Events (SAEs)

An SAE is defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, leads to a congenital anomaly/birth defect in the offspring of a participant, is an important medical event that may require intervention to prevent any of the above mentioned criteria and/or may expose the subject to danger, even though the event is not immediately life threatening or fatal or does not result in hospitalization.

Time frame:
From first vaccination (Day 1) through end of study (Day 360)
Reported as:
Number · percentage of participants
Percentage of Participants With Serious Adverse Events (SAEs)
percentage of participantsGroup 1: YF-17D + Placebo/TDV/TDVGroup 2: TDV + Placebo/TDV/YF-17DGroup 3: TDV + YF-17D/TDV/Placebo
Percentage of Participants With Serious Adverse Events (SAEs)4.33.32.3

Adverse events

Collected over All-Cause Mortality and Serious Adverse Events: From first vaccination (Day 1) through end of study (Day 360); Other Adverse Events: From any vaccination (Day 1, Day 90, and Day 180) up to 28 days post vaccination.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group 1: YF-17D + Placebo/TDV/TDV0/300 (0%)13/300 (4.3%)11/300 (3.7%)
Group 2: TDV + Placebo/TDV/YF-17D1/300 (0.3%)10/300 (3.3%)23/300 (7.7%)
Group 3: TDV + YF-17D/TDV/Placebo1/300 (0.3%)7/300 (2.3%)19/300 (6.3%)
Most frequent serious events
Showing 10 of 32
Most frequent serious events
EventGroup 1: YF-17D + Placebo/TDV/TDVGroup 2: TDV + Placebo/TDV/YF-17DGroup 3: TDV + YF-17D/TDV/Placebo
PneumoniaInfections and infestations0/3001/3002/300
Intraductal proliferative breast lesionNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/3000/3000/300
Cardiac arrestCardiac disorders0/3001/3000/300
HypothyroidismEndocrine disorders0/3000/3001/300
Abdominal painGastrointestinal disorders0/3001/3000/300
Alcoholic pancreatitisGastrointestinal disorders0/3001/3000/300
Inguinal herniaGastrointestinal disorders1/3000/3000/300
Large intestinal obstructionGastrointestinal disorders0/3001/3000/300
MegacolonGastrointestinal disorders0/3001/3000/300
Peptic ulcerGastrointestinal disorders1/3000/3000/300
Most frequent other events
Most frequent other events
EventGroup 1: YF-17D + Placebo/TDV/TDVGroup 2: TDV + Placebo/TDV/YF-17DGroup 3: TDV + YF-17D/TDV/Placebo
Upper respiratory tract infectionInfections and infestations6/30013/3004/300
Injection site bruisingGeneral disorders4/3005/30010/300
Injection site pruritusGeneral disorders3/3007/3008/300

Baseline characteristics

Safety Set included all randomized participants who received at least 1 dose of the trial vaccines.

Age, Continuous
Age, Continuous(years)Group 1: YF-17D + Placebo/TDV/TDVGroup 2: TDV + Placebo/TDV/YF-17DGroup 3: TDV + YF-17D/TDV/PlaceboTotal
Mean41.7 ± 12.4140.0 ± 12.9141.4 ± 12.6741.0 ± 12.67
Sex: Female, Male
Sex: Female, Male(Participants)Group 1: YF-17D + Placebo/TDV/TDVGroup 2: TDV + Placebo/TDV/YF-17DGroup 3: TDV + YF-17D/TDV/PlaceboTotal
Female167170176513
Male133130124387
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Group 1: YF-17D + Placebo/TDV/TDVGroup 2: TDV + Placebo/TDV/YF-17DGroup 3: TDV + YF-17D/TDV/PlaceboTotal
Hispanic or Latino26253182
Not Hispanic or Latino272270266808
Unknown or Not Reported25310
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Group 1: YF-17D + Placebo/TDV/TDVGroup 2: TDV + Placebo/TDV/YF-17DGroup 3: TDV + YF-17D/TDV/PlaceboTotal
American Indian or Alaska Native3227
Asian34714
Native Hawaiian or Other Pacific Islander2013
Black or African American7710384264
White205186201592
More than one race5027
Unknown or Not Reported55313
Height
Height(cm)Group 1: YF-17D + Placebo/TDV/TDVGroup 2: TDV + Placebo/TDV/YF-17DGroup 3: TDV + YF-17D/TDV/PlaceboTotal
Mean171.3 ± 9.29170.1 ± 9.05170.5 ± 8.85170.6 ± 9.07
Weight
Weight(kg)Group 1: YF-17D + Placebo/TDV/TDVGroup 2: TDV + Placebo/TDV/YF-17DGroup 3: TDV + YF-17D/TDV/PlaceboTotal
Mean82.40 ± 15.4078.52 ± 14.6580.87 ± 16.9480.60 ± 15.75
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)Group 1: YF-17D + Placebo/TDV/TDVGroup 2: TDV + Placebo/TDV/YF-17DGroup 3: TDV + YF-17D/TDV/PlaceboTotal
Mean28.00 ± 4.2927.07 ± 4.3027.66 ± 4.4927.58 ± 4.37
08

Study locations

11 sites
  • Coastal Clinical Research Inc
    Mobile, Alabama 36608, United States
  • Empire Clinical Research
    Pomona, California 91767, United States
  • Advanced Clinical Research
    Meridian, Idaho 83462, United States
  • Johnson County Clin-Trials
    Lenexa, Kansas 66219, United States
  • Center for Pharmaceutical Research
    Kansas City, Missouri 64114, United States
  • Meridian Clinical Research LLC
    Omaha, Nebraska 68134, United States
  • Regional Clinical Research Inc.
    Endwell, New York 13760, United States
  • Rapid Medical Research Inc
    Cleveland, Ohio 44122, United States
  • Tekton Research
    Austin, Texas 78745, United States
  • Advanced Clinical Research
    West Jordan, Utah 84088, United States
  • Clinical Research Associates of Tidewater
    Norfolk, Virginia 23507, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda makes patient-level, de-identified data sets and associated documents available for all interventional studies after applicable marketing approvals and commercial availability have been received (or program is completely terminated), an opportunity for the primary publication of the research and final report development has been allowed, and other criteria have been met as set forth in Takeda's Data Sharing Policy (see www.TakedaClinicalTrials.com for details). To obtain access, researchers must submit a legitimate academic research proposal for adjudication by an independent review panel, who will review the scientific merit of the research and the requestor's qualifications and conflict of interest that can result in potential bias. Once approved, qualified researchers who sign a data sharing agreement are provided access to these data in a secure research environment.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2018 to primary completion in May 2018, 2 months.

Results were first posted in Oct 2020, 2 years 4 months after primary completion. A results delay was requested in May 2019.

Of 21 phase 3 interventional studies under Dengue, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 30. This study's 2 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2017
First posted
Nov 17, 2017
StartActual
Feb 28, 2018
Primary completionActual
May 9, 2018
CompletionActual
May 22, 2019
Results delay requested
May 21, 2019
Results first posted
Oct 8, 2020
Last update
Oct 8, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 8, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03342898
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Nov 17, 2017
Start date
Feb 28, 2018
Primary completion
May 9, 2018
Completion
May 22, 2019
Results posted
Oct 8, 2020
Last update
Oct 8, 2020

Study contacts

Medical Director Clinical Science
study director · Takeda

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion